Sumitomo Mitsui Financial Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Sumitomo Mitsui Financial Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-96	Closed	-$66K	–	211
2022 Q1	$66K	Buy	96 +26	+37%	+$16.4K	﹤0.01%	172
2021 Q4	$45K	Buy	70 +10	+17%	+$6.15K	﹤0.01%	171
2021 Q3	$36K	Buy	+60	New	+$37.2K	﹤0.01%	173
2019 Q3	–	Sell	-159	Closed	-$49K	–	142
2019 Q2	$49K	Buy	+159	New	+$52.9K	﹤0.01%	103
2018 Q4	–	Sell	-116	Closed	-$47K	–	124
2018 Q3	$47K	Buy	+116	New	+$44.1K	﹤0.01%	100

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Sumitomo Mitsui Financial Group's REGN Position: Q2 2022 in Review

Sumitomo Mitsui Financial Group sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 96 shares — an estimated $66K sold.

Sumitomo Mitsui Financial Group first reported a position in REGN in Q3 2018 and held it in 5 quarters. The position peaked at $66K in Q1 2022. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

Sumitomo Mitsui Financial Group reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Sumitomo Mitsui Financial Group sold 96 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $66K.
Sumitomo Mitsui Financial Group first reported a position in Regeneron Pharmaceuticals in Q3 2018 and held it in 5 quarters.
Sumitomo Mitsui Financial Group's Regeneron Pharmaceuticals position peaked at $66K in Q1 2022.
1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Sumitomo Mitsui Financial Group's 13F filing for Q2 2022, filed 9 Aug 2022.